• 12955 Citations
  • 39 h-Index
1973 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Article

A biszfo szfo nát-keze lés során és zlelhet o vese funkci ó-válto zás vizsg álata emlorákos betege inknél

Horváth, Z., Farkas, P., Ganofszky, E., Hitre, E., Juhos, É., Nagy, T., Rubovszky, G., Szabó, E. & Láng, I., dec. 1 2008, In : Magyar onkologia. 52, 1, p. 49-55 7 p.

Research output: Article

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials

Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Price, K. N., Coates, A. S., Goldhirsch, A. & Gelber, R. D., júl. 1 2016, In : Journal of Clinical Oncology. 34, 19, p. 2221-2230 10 p.

Research output: Article

75 Citations (Scopus)

Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TExT and Soft

Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Pinotti, G., Di Leo, A., Coates, A. S., Goldhirsch, A., Gelber, R. D. & Regan, M. M., ápr. 20 2020, In : Journal of Clinical Oncology. 38, 12, p. 1293-1303 11 p.

Research output: Article

Open Access
9 Citations (Scopus)

A Case-Control Study of Gallbladder Cancer in Hungary

Nakadaira, H., Lang, I., Szentirmay, Z., Hitre, E., Kaster, M. & Yamamoto, M., 2009, In : Asian Pacific Journal of Cancer Prevention. 10, 5, p. 833-836 4 p.

Research output: Article

11 Citations (Scopus)
3 Citations (Scopus)

Action of cyclic nucleotides in antibody dependent cellular cytotoxicity reactions

Lang, I., Kalmar, L. & Gergely, P., jan. 1 1978, In : Kiserletes Orvostudomany. 30, 3, p. 300-305 6 p.

Research output: Article

Activity tests on concanavalin A-induced suppressor cells in autologous and allogenous systems

Gergely, P., Gonzalez Cabello, R., Lang, I. & Kalmar, L., jan. 1 1980, In : Kiserletes Orvostudomany. 32, 5, p. 514-518 5 p.

Research output: Article

Adjuvant Anti-HER2 Therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients

Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno-Aspitia, A., Piccart, M. & 2 others, Gelber, R. D. & De Azambuja, E., jan. 1 2019, In : Journal of the National Cancer Institute. 111, 1, djy094.

Research output: Article

23 Citations (Scopus)

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial

Francis, P., Crown, J., Di Leo, A., Buyse, M., Balil, A., Andersson, M., Nordenskjöld, B., Lang, I., Jakesz, R., Vorobiof, D., Gutiérrez, J., Van Hazel, G., Dolci, S., Jamin, S., Bendahmane, B., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M. & Piccart-Gebhart, M., jan. 2008, In : Journal of the National Cancer Institute. 100, 2, p. 121-133 13 p.

Research output: Article

125 Citations (Scopus)

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., Ciruelos, E., Stearns, V., Bonnefoi, H. R., Martino, S., Geyer, C. E., Pinotti, G., Puglisi, F., Crivellari, D., Ruhstaller, T., Winer, E. P. & 13 others, Rabaglio-Poretti, M., Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Bernhard, J., Luo, W., Ribi, K., Viale, G., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Francis, P. A., 2014, In : New England Journal of Medicine. 371, 2, p. 107-118 12 p.

Research output: Article

327 Citations (Scopus)

Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial

Piccart-Gebhart, M., Holmes, E., Baselga, J., De Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., McCullough, A. E., Dolci, S., McFadden, E., Holmes, A. P., Tonghua, L., Eidtmann, H., Dinh, P., Di Cosimo, S., Harbeck, N., Tjulandin, S. & 15 others, Im, Y. H., Huang, C. S., Díeras, V., Hillman, D. W., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Gomez, H., Suter, T., Gelber, R. D. & Perez, E. A., ápr. 1 2016, In : Journal of Clinical Oncology. 34, 10, p. 1034-1042 9 p.

Research output: Article

180 Citations (Scopus)

Adjuvant ovarian suppression in premenopausal breast cancer

Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., Martino, S., Davidson, N. E., Geyer, C. E., Walley, B. A., Coleman, R., Kerbrat, P., Buchholz, S., Ingle, J. N., Winer, E. P. M., Rabaglio-Poretti, M. & 9 others, Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Colleoni, M., Viale, G., Coates, A. S., Goldhirsch, A. & Gelber, R. D., jan. 1 2015, In : New England Journal of Medicine. 372, 5, p. 436-446 11 p.

Research output: Article

327 Citations (Scopus)

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a " standard chemotherapy regimen": The CASA randomized trial

Crivellari, D., Gray, K. P., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K. N., Láng, I., Gianni, L., Spazzapan, S., Pinotti, G., Lüthi, J. M., Gelber, R. D., Regan, M. M., Colleoni, M., Castiglione-Gertsch, M., Maibach, R., Rabaglio, M., Coates, A. S. & Goldhirsch, A., ápr. 2013, In : Breast. 22, 2, p. 130-137 8 p.

Research output: Article

29 Citations (Scopus)

Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

Von Minckwitz, G., Procter, M., De Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M. & Baselga, J., júl. 13 2017, In : New England Journal of Medicine. 377, 2, p. 122-131 10 p.

Research output: Article

389 Citations (Scopus)
11 Citations (Scopus)

A hanging manover újabb indikációi a májsebészetben.

Jakab, F., Dede, K., Láng, I., Bursics, A. & Mersich, T., dec. 2012, In : Magyar sebészet. 65, 6, p. 407-415 9 p.

Research output: Article

A humán antitest-dependens celluláris cytotoxicitás (ADCC) vizsgálata allogén rendszerben.

Láng, I., Fekete, B., Gergely, P. & Petrányi, G., júl. 24 1977, In : Orvosi hetilap. 118, 30, p. 1763-1765 3 p.

Research output: Article

3 Citations (Scopus)

A modern emlo{double acute}sebészet onkoplasztikai kihívásai

Mátrai, Z., Gulyás, G., Tóth, L., Polgár, C., Bidlek, M., Szabó, É., Láng, I., Horváth, Z., Udvarhelyi, N., Kunos, C., Sávolt, Á., Pesthy, P. & Kásler, M., 2011, In : Magyar onkologia. 55, 1, p. 40-52 13 p.

Research output: Article

8 Citations (Scopus)

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study

Colleoni, M., Giobbie-Hurder, A., Regan, M. M., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Láng, I., Smith, I., Chirgwin, J., Pienkowski, T., Wardley, A., Price, K. N., Gelber, R. D., Coates, A. S. & Goldhirsch, A., márc. 20 2011, In : Journal of Clinical Oncology. 29, 9, p. 1117-1124 8 p.

Research output: Article

101 Citations (Scopus)
2 Citations (Scopus)

Antibody dependent and spontaneous lymphocyte mediated cytotoxicity in normal subjects, patients with SLE, and malignancies

Lang, I., Benczur, M., Varga, M., Gergely, P. & Petrányi, G., dec. 1 1977, In : Acta medica Academiae Scientiarum Hungaricae. 34, 3, p. 123-127 5 p.

Research output: Article

6 Citations (Scopus)

Antibody-dependent cellular cytocoxicity in systemic lupus erythematosus

Lang, I., Fekete, B., Paloczi, K., Sonkoly, I., Szegedi, G., Török, K., Gergely, P. & Petrányi, G., dec. 1 1977, In : Acta medica Academiae Scientiarum Hungaricae. 34, 4, p. 259-265 7 p.

Research output: Article

4 Citations (Scopus)

Antibody-dependent cellular cytotoxic activity in patients with Hodgkin disease

Lang, I., Berenyi, E., Szegedi, G., Török, K., Fekete, B. & Gergely, P., dec. 1 1977, In : Acta medica Academiae Scientiarum Hungaricae. 34, 4, p. 241-245 5 p.

Research output: Article

Antibody dependent cellular cytotoxicity of lymphocytes in patients with renal diseases of immunopathological origin

Lang, I., Kenez, B., Nagy, Z. K., Sonkoly, I., Pálóczi, K., Szegedi, G., Fekete, B. & Gergely, P., dec. 1 1978, In : Clinical Nephrology. 9, 3, p. 111-114 4 p.

Research output: Article

4 Citations (Scopus)
1 Citation (Scopus)

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Bennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T. Y., Pover, G. M., Morris, C. D. & Douillard, J. Y., okt. 1 2011, In : Investigational New Drugs. 29, 5, p. 1021-1028 8 p.

Research output: Article

95 Citations (Scopus)

A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer

Dittrich, C., Solska, E., Manikhas, A., Eniu, A., Tjulandin, S., Anghel, R., Musib, L., Frimodt-Moller, B., Liu, Y., Krejcy, K. & Láng, I., máj. 2012, In : Cancer Investigation. 30, 4, p. 309-316 8 p.

Research output: Article

4 Citations (Scopus)

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

Martin, M., Bonneterre, J., Geyer, C. E., Ito, Y., Ro, J., Lang, I., Kim, S. B., Germa, C., Vermette, J., Wang, K., Wang, K. & Awada, A., dec. 1 2013, In : European Journal of Cancer. 49, 18, p. 3763-3772 10 p.

Research output: Article

86 Citations (Scopus)

A simple allogeneic test system for the study of antibody-dependent cellular cytotoxicity (ADCC) in man.

Láng, I., Fekete, B., Gergely, P. & Petrányi, G., dec. 1 1977, In : Haematologia. 11, 1-2, p. 85-91 7 p.

Research output: Article

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K. N., Gelber, R. D., Coates, A. S. & Thürlimann, B., nov. 1 2011, In : The Lancet Oncology. 12, 12, p. 1101-1108 8 p.

Research output: Article

268 Citations (Scopus)

A tripla-negatív emlokarcinóma - Irodalmi áttekintés

Rubovszky, G., Udvarhelyi, N., Horváth, Z., Láng, I. & Kásler, M., dec. 1 2010, In : Magyar onkologia. 54, 4, p. 325-335 11 p.

Research output: Article

4 Citations (Scopus)

Az emloárák belgyógyászati onkológiai (gyógyszeres) kezelése

Láng, I., Kahán, Z., Pintér, T., Dank, M., Boér, K., Pajkos, G., Faluhelyi, Z., Pikó, B., Eckhardt, S. & Horváth, Z., szept. 1 2010, In : Magyar onkologia. 54, 3, p. 237-254 18 p.

Research output: Article

12 Citations (Scopus)

Az emlorák korszeru gyógyszeres kezelése

Láng, I., Kahán, Z., Hitre, E., Dank, M., Rubovszky, G., Horváth, Z. & Kásler, M., jan. 1 2012, In : Orvosi hetilap. 153, 2, p. 56-65 10 p.

Research output: Article

3 Citations (Scopus)

Az emlorák korszeru képalkotó diagnosztikája: nukleárismedicina-technikák

Katalin, B., István, S., Balázs, M., Zsolt, H., István, L. & Miklós, K., jan. 1 2012, In : Orvosi hetilap. 153, 1, p. 14-21 8 p.

Research output: Article

Az emlótumor csontveló mikrometasztázisának klinikai jelentósége.

Dubecz, S., Csuka, O., Török, K., Vasas, N., Péley, G., Doleschal, Z., Sulyok, Z., Láng, I. & Köves, I., aug. 2003, In : Magyar sebészet. 56, 3-4, p. 108-112 5 p.

Research output: Article

1 Citation (Scopus)

Az epeúti carcinomák gyógyszeres kezelé sének lehetõségei. Múlt - Jelen - Jóvo

Gábor, R., Erika, H. & István, L., júl. 24 2013, In : Lege Artis Medicinae. 23, 5-6, p. 255-261 7 p.

Research output: Article

4 Citations (Scopus)

Az indometacin lymphocyta proliferációt fokozó hatása in vivo.

Kalmár, L., Rhenzo, G. C., Láng, I., Gergely, P. & Fehér, J., nov. 24 1985, In : Orvosi hetilap. 126, 47, p. 2889-2893 5 p.

Research output: Article

Az MR-vizsgálat szerepe a rectumcarcinomák terápiájának meghatározásában

Jederán, É., Mátrai, Z., Tóth, L., Lövey, J., Láng, I., Hitre, E., Naszádos, G. & Godény, M., 2012, In : Magyar onkologia. 56, 3, p. 179-186 8 p.

Research output: Article

1 Citation (Scopus)

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial

Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D., Osborne, S., Andre, N., Waterkamp, D. & Saunders, M. P., okt. 1 2013, In : The Lancet Oncology. 14, 11, p. 1077-1085 9 p.

Research output: Article

348 Citations (Scopus)

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., Villanueva, C., Romieu, G., Lang, I., Ciruelos, E., De Laurentiis, M., Veyret, C., de Ducla, S., Freudensprung, U., Srock, S. & Gligorov, J., okt. 1 2014, In : The Lancet Oncology. 15, 11, p. 1269-1278 10 p.

Research output: Article

98 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, Open-label, Non-inferiority, Phase 3 TURANDOT trial

Lang, I., Brodowicz, T., Ryvo, L., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Messinger, D. & Zielinski, C., febr. 1 2013, In : The Lancet Oncology. 14, 2, p. 125-133 9 p.

Research output: Article

78 Citations (Scopus)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Zielinski, C., Láng, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Zvirbule, Z., Steger, G. G., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D. & Brodowicz, T., szept. 1 2016, In : The Lancet Oncology. 17, 9, p. 1230-1239 10 p.

Research output: Article

30 Citations (Scopus)

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., Colleoni, M., Pienkowski, T., Nogaret, J. M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A. & Coates, A. S., jan. 1 2009, In : Annals of Oncology. 20, 9, p. 1489-1498 10 p.

Research output: Article

107 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor exemestane: A phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 346-347 2 p.

Research output: Article

7 Citations (Scopus)

Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausalwomen evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer

Moy, B., Neven, P., Lebrun, F., Bellet, M., Xu, B., Sarosiek, T., Chow, L., Goss, P., Zacharchuk, C., Leip, E., Turnbull, K., Bardy-Bouxin, N., Duvillié, L. & Láng, I., 2014, In : Oncologist. 19, 4, p. 348-349 2 p.

Research output: Article

13 Citations (Scopus)

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study

Rubovszky, G., Láng, I., Ganofszky, E., Horváth, Z., Juhos, É., Nagy, T., Szabó, E., Szentirmay, Z., Budai, B. & Hitre, E., dec. 1 2013, In : European Journal of Cancer. 49, 18, p. 3806-3812 7 p.

Research output: Article

35 Citations (Scopus)
34 Citations (Scopus)